Background CD161⁺ regulatory T cells (Tregs) are involved in rheumatoid arthritis (RA) pathogenesis. This study aimed to investigate the levels of circulating CD161⁺ Tregs in RA patients and to evaluate their associations with clinical features, laboratory indicators, and therapeutic responses. Methods A total of 172 RA patients meeting the 2010 ACR/EULAR criteria and 110 age- and sex-matched healthy controls (HCs) were enrolled. The proportion of CD161⁺ Tregs in peripheral blood was quantified by flow cytometry. Correlations between CD161⁺ Treg levels and clinical manifestations, laboratory parameters, and disease activity scores (DAS28) were assessed. Twenty-four RA patients were longitudinally followed to assess post-treatment changes in CD161⁺ Tregs and disease activity. Results  The proportions of CD161⁺ Tregs of the total Treg and CD4⁺ T cell populations were significantly elevated in RA patients compared to HCs (P < 0.001). Higher CD161⁺ Treg levels were associated with smoking history (P = 0.033) and inversely correlated with the presence of dry eye sicca (P = 0.030). These subsets showed positive correlations with IgA, IgM, rheumatoid factor (RF), RF-IgG, TNF-α+CD4+ T cell, Th17 and DAS28-ESR (P < 0.05), while exhibiting negative correlations with naïve Th cells and effector T (Teff) cells (P < 0.05). CD161⁺ Treg levels were higher in patients with long-standing RA (LRA) than in HCs (P < 0.05), and in patients with high disease activity (DAS28-ESR > 5.1) compared to those with moderate/low disease activity (P < 0.05). After treatment, decreased CD161⁺ Treg and disease activity scores were observed (P < 0.05), which were particularly pronounced in the group receiving csDMARDs combined with tocilizumab (an IL-6 inhibitor). However, csDMARDs alone or in combination with JAK inhibitors showed no or only partial efficacy. Conclusion CD161⁺ Tregs are elevated in RA and associated with disease activity and immunologic indicators. CD161⁺ Tregs might serve as a biomarker for assessing RA disease activity. <Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec colname="c1" colnum="1" /> <colspec colname="c2" colnum="2" /> <tbody> <row> <entry align="left" nameend="c2" namest="c1"> Key Points • The proportion of circulating CD161⁺ regulatory T cells is significantly increased in rheumatoid arthritis patients compared to healthy controls. • Higher CD161⁺ Treg levels correlate positively with disease activity scores (DAS28-ESR) and key serological markers (RF, IgA, IgM). • CD161⁺ Treg levels decreased significantly following effective therapy, paralleling reductions in disease activity, particularly in the group receiving csDMARDs combined with tocilizumab. • CD161⁺ Tregs show positive correlations with pro-inflammatory cells (TNF-α+CD4+T cell, Th17) and peripheral T follicular helper cells, underscoring their role in RA immunopathology. </entry> </row> </tbody> </tgroup> </Table>

CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis

期刊论文
发表日期：

2026年3月20日

查看全文

Ziyi Song,
Danxue Zhu,
Feng Sun,
Jiayi Geng,
Chuanhui Xu,
Junyi Jiang,
Wenjuan Zhang,
Xiaolin Sun,
Zhanguo Li

摘要

Background

CD161⁺ regulatory T cells (Tregs) are involved in rheumatoid arthritis (RA) pathogenesis. This study aimed to investigate the levels of circulating CD161⁺ Tregs in RA patients and to evaluate their associations with clinical features, laboratory indicators, and therapeutic responses.

Methods

A total of 172 RA patients meeting the 2010 ACR/EULAR criteria and 110 age- and sex-matched healthy controls (HCs) were enrolled. The proportion of CD161⁺ Tregs in peripheral blood was quantified by flow cytometry. Correlations between CD161⁺ Treg levels and clinical manifestations, laboratory parameters, and disease activity scores (DAS28) were assessed. Twenty-four RA patients were longitudinally followed to assess post-treatment changes in CD161⁺ Tregs and disease activity.

Results

The proportions of CD161⁺ Tregs of the total Treg and CD4⁺ T cell populations were significantly elevated in RA patients compared to HCs (P < 0.001). Higher CD161⁺ Treg levels were associated with smoking history (P = 0.033) and inversely correlated with the presence of dry eye sicca (P = 0.030). These subsets showed positive correlations with IgA, IgM, rheumatoid factor (RF), RF-IgG, TNF-α⁺CD4⁺ T cell, Th17 and DAS28-ESR (P < 0.05), while exhibiting negative correlations with naïve Th cells and effector T (Teff) cells (P < 0.05). CD161⁺ Treg levels were higher in patients with long-standing RA (LRA) than in HCs (P < 0.05), and in patients with high disease activity (DAS28-ESR > 5.1) compared to those with moderate/low disease activity (P < 0.05). After treatment, decreased CD161⁺ Treg and disease activity scores were observed (P < 0.05), which were particularly pronounced in the group receiving csDMARDs combined with tocilizumab (an IL-6 inhibitor). However, csDMARDs alone or in combination with JAK inhibitors showed no or only partial efficacy.

Conclusion

CD161⁺ Tregs are elevated in RA and associated with disease activity and immunologic indicators. CD161⁺ Tregs might serve as a biomarker for assessing RA disease activity.

Key Points

• The proportion of circulating CD161⁺ regulatory T cells is significantly increased in rheumatoid arthritis patients compared to healthy controls.

• Higher CD161⁺ Treg levels correlate positively with disease activity scores (DAS28-ESR) and key serological markers (RF, IgA, IgM).

• CD161⁺ Treg levels decreased significantly following effective therapy, paralleling reductions in disease activity, particularly in the group receiving csDMARDs combined with tocilizumab.

• CD161⁺ Tregs show positive correlations with pro-inflammatory cells (TNF-α+CD4+T cell, Th17) and peripheral T follicular helper cells, underscoring their role in RA immunopathology.